Nektar Therapeutics NKTR
NASDAQ NKTR
$39.22 +2.58 (+7.04%)
At close: Oct 20, 2026 · 4:00 PM EDT

Nektar Therapeutics (NKTR) Convertible Debt (2010 - 2011)

Updated

Nektar Therapeutics (NKTR) recorded Convertible Debt of $214.96 million in Q4 2011, unchanged from $214.96 million a year earlier.

Analysis

Nektar Therapeutics (NKTR) Convertible Debt (2010 - 2011) Analysis & Trends

Starting with Q4 2010, Nektar Therapeutics' Convertible Debt history includes 4 quarters.

  • Across earlier years, Convertible Debt came in at $214.96 million in FY2010.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,146.94 Bn 1,115.53 Bn 19.71 Bn
2 Johnson & Johnson 624.96 Bn 543.49 Bn 17.26 Bn
3 AbbVie 510.15 Bn 483.27 Bn 12.70 Bn
4 Merck 366.13 Bn 320.51 Bn 12.21 Bn
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn
6 Astrazeneca 261.93 Bn 235.62 Bn 12.86 Bn
7 Amgen 236.51 Bn 191.91 Bn 7.24 Bn
8 Gilead Sciences 194.27 Bn 168.47 Bn 6.22 Bn
9 Pfizer 171.74 Bn 118.39 Bn 10.94 Bn
10 Nektar Therapeutics 1.29 Bn -483.40 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2011 214.96 Mn
Jun 30, 2011 214.96 Mn
Mar 31, 2011 214.96 Mn
Dec 31, 2010 214.96 Mn
API Access

Nektar Therapeutics Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=NKTR&period=max&api_key=YOUR_API_KEY